


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims

1. (currently amended) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R₁ is hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl;

R₂ and R₃ are each independently is hydrogen, or halogen, hydroxyl, protected hydroxyl, or an aliphatic, heteroaliphatic, alicyclic or aryl moiety; or R₁ and R₂, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

or R₁ and R₃, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R₄ is hydrogen or halogen;

R₅ is hydrogen or an oxygen protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, or alkyloxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;


R₉ is NR₁₂R₁₃;

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl; or a protecting group, and each of R₁₂ and R₁₃ are

optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, R₁₀ is hydrogen, hydroxyl, protected hydroxyl, or amino, or protected amino; R₁₁ is hydrogen, hydroxyl or protected hydroxyl; X is absent or is O, NH, or N-alkyl, CH₂ or S; Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, Θ-C=O, or CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or aliphatic, or R₁₇ and R₁₈ taken together is -O-, or -CH₂- or NR₁₉, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z are connected by a single or double bond.

2. (canceled)

3. (currently amended) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein: R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ is methyl; and R₃ are each independently is hydrogen, or halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, or alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is NR₁₂R₁₃;

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, alkylaryl, or a protecting group, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,


R₁₀ is hydrogen, hydroxyl, protected hydroxyl, or amino, or protected amine;

R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, or N-alkyl, CH₂ or S;


Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, Θ-C=O, or CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or C₁₋₆alkyl, or R₁₇ and R₁₈ taken together is -O-, or -CH₂- or NR₁₉, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z are connected by a single or double bond.

4. (original) The compound of claim 3, where X is oxygen and n is 1.
5. (original) The compound of claim 3, where R₄ is halogen.
6. (original) The compound of claim 3, where R₄ is fluorine.
7. (original) The compound of claim 3, where Y and Z together represent -CH=CH-
8. (original) The compound of claim 3, where Y and Z together represent trans -CH=CH-.
9. (currently amended) The compound of claim 3, wherein R₁ and R₂ are each is methyl and R₃ is hydrogen and the compound is of the structure:



wherein R₄-R₁₁, n, X, Y and Z are as defined in claim 3.

10. (original) The compound of claim 9, wherein X is oxygen and n is 1.
11. (original) The compound of claim 9, wherein R₄ is halogen.
12. (original) The compound of claim 9, wherein Y and Z together represent -CH=CH-.
13. (original) The compound of claim 9, wherein X is oxygen, n is 1, R₄ is halogen and Y and Z together represent -CH=CH-.
14. (original) The compound of claim 12 or 13 wherein -CH=CH- is trans.
15. (canceled)
16. (canceled)
17. (currently amended) The compound of claim ~~15~~₃, wherein R₄ is halogen hydrogen.
18. (currently amended) The compound of claim ~~15~~₁₇, wherein Y and Z together represent -CH=CH-.
19. (currently amended) The compound of claim ~~15~~₁₇, wherein R₁ and R₂ are each is methyl and R₃ is hydrogen.
20. (currently amended) The compound of claim ~~15~~₁₇, wherein X is oxygen, n is 1, R₁ and R₂ are each is methyl, R₃ is hydrogen, R₄ is halogen, and Y and Z together represent -CH=CH-.
21. (original) The compound of claim 18 or 20, wherein -CH=CH- is trans.
22. (previously presented) The compound of claim 1, wherein the compound is of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof.

23-36. (canceled)

37. (currently amended) A pharmaceutical composition comprising:
| a compound of any one of claims 1, 3, 9 and ~~15~~ 17; or pharmaceutically acceptable salt,
| ester or salt of ester thereof; and a pharmaceutically acceptable carrier.

38. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit NF- κ B activation.

39-42. (canceled)


43. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to have an anti-inflammatory effect.


44. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to treat psoriasis.

45. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to reduce skin photodamage.

46-65. (canceled)

66. (previously presented) The pharmaceutical composition of claim 37 wherein the compound has the structure:






or pharmaceutically acceptable salt, ester or salt of ester thereof.

67-127. (canceled)


128. (currently amended) A compound of claim 127, wherein R₁₂ is methyl, ethyl, propyl, isopropyl or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl and wherein R₁₃ is hydrogen or C₁₋₆alkyl.

129. (previously presented) A compound of the formula:




or a pharmaceutically acceptable salt, ester or salt of ester thereof.

130. (previously presented) A compound of claim 129, wherein the compound is of the formula:



131. (previously presented) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof.

132. (previously presented) A compound of claim 131, wherein the compound is of the formula:

